NYSE:GKOS - New York Stock Exchange, Inc. - US3773221029 - Common Stock - Currency: USD
NYSE:GKOS (4/22/2025, 3:30:01 PM)
89.61
+1.31 (+1.48%)
The current stock price of GKOS is 89.61 USD. In the past month the price decreased by -13.65%. In the past year, price decreased by -11.24%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.5 | 227.97B | ||
ISRG | INTUITIVE SURGICAL INC | 64.96 | 170.59B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.74 | 140.11B | ||
SYK | STRYKER CORP | 28.51 | 132.64B | ||
MDT | MEDTRONIC PLC | 15.6 | 106.81B | ||
BDX | BECTON DICKINSON AND CO | 14.3 | 57.13B | ||
EW | EDWARDS LIFESCIENCES CORP | 26.85 | 41.36B | ||
IDXX | IDEXX LABORATORIES INC | 37.33 | 34.03B | ||
RMD | RESMED INC | 24.14 | 31.34B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 13.67 | 28.11B | ||
DXCM | DEXCOM INC | 40.11 | 25.95B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 15.37 | 22.68B |
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in Aliso Viejo, California and currently employs 995 full-time employees. The company went IPO on 2015-06-25. The company develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
GLAUKOS CORP
1 Glaukos Way
Aliso Viejo CALIFORNIA 92672 US
CEO: Thomas W. Burns
Employees: 907
Company Website: https://www.glaukos.com
Investor Relations: https://investors.glaukos.com/
Phone: 19493679600
The current stock price of GKOS is 89.61 USD. The price increased by 1.48% in the last trading session.
The exchange symbol of GLAUKOS CORP is GKOS and it is listed on the New York Stock Exchange, Inc. exchange.
GKOS stock is listed on the New York Stock Exchange, Inc. exchange.
21 analysts have analysed GKOS and the average price target is 171.91 USD. This implies a price increase of 91.84% is expected in the next year compared to the current price of 89.61. Check the GLAUKOS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GLAUKOS CORP (GKOS) has a market capitalization of 5.12B USD. This makes GKOS a Mid Cap stock.
GLAUKOS CORP (GKOS) currently has 907 employees.
GLAUKOS CORP (GKOS) has a support level at 85.49 and a resistance level at 89.44. Check the full technical report for a detailed analysis of GKOS support and resistance levels.
The Revenue of GLAUKOS CORP (GKOS) is expected to grow by 26.9% in the next year. Check the estimates tab for more information on the GKOS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GKOS does not pay a dividend.
GLAUKOS CORP (GKOS) will report earnings on 2025-04-30, after the market close.
GLAUKOS CORP (GKOS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.9).
The outstanding short interest for GLAUKOS CORP (GKOS) is 6.47% of its float. Check the ownership tab for more information on the GKOS short interest.
ChartMill assigns a fundamental rating of 4 / 10 to GKOS. GKOS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months GKOS reported a non-GAAP Earnings per Share(EPS) of -1.9. The EPS increased by 16.3% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -15.02% | ||
ROE | -19.09% | ||
Debt/Equity | 0.09 |
ChartMill assigns a Buy % Consensus number of 84% to GKOS. The Buy consensus is the average rating of analysts ratings from 21 analysts.
For the next year, analysts expect an EPS growth of 47.44% and a revenue growth 26.9% for GKOS